Avatrombopag vs. Placebo for CIT in GI Malignancies

Status Recruiting

Clinical Trial Summary

The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: - Avatrombopag (a thrombopoietin receptor agonist) - Matching placebo

Clinical Trial Description

This is a randomized, double-blinded, placebo-controlled, multicenter phase 2 clinical trial evaluating Avatrombopag versus placebo for Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies. Avatrombopag may increase or stimulate megakaryocytes, which aid in producing blood platelets, resulting in an increased production of platelets. - Participants will be "randomized" into one of the study groups: Group A: Avatrombopag or Group B: Matching placebo. Randomization means that a participant is put into a group by chance. - All patients who complete the study (whether they received avatrombopag or placebo) have the opportunity to receive avatrombopag to treat CIT through a special free drug program available only to the participants of this study. The U.S. Food and Drug Administration (FDA) has not approved avatrombopag for CIT, but it has been approved for other uses. Study procedures include screening for eligibility, treatment visits, and blood tests. Participants will receive the study treatment or placebo for up to seven weeks and will be followed for up to 42 days after the last dose. It is expected that about 60 people will take part in this research study. Swedish Orphan Biovitrum (Sobi), biopharmaceutical company, is supporting this research study by providing the study drugs and funding. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05772546
Study type	Interventional
Source	Massachusetts General Hospital
Contact	Hanny Al-Samkari, MD
Phone	857-242-0719
Email	hal-samkari@mgh.harvard.edu
Status	Recruiting
Phase	Phase 2
Start date	November 1, 2023
Completion date	July 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT00068003` - Harvesting Cells for Experimental Cancer Treatments
Not yet recruiting	`NCT05044312` - Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis	N/A
Active, not recruiting	`NCT05053191` - Advancing Nursing Practices in Hospital Oncology Care	N/A
Completed	`NCT03611309` - Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members	N/A
Recruiting	`NCT03602677` - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage	N/A
Recruiting	`NCT03190941` - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients	Phase 1/Phase 2
Not yet recruiting	`NCT06398314` - Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors	N/A
Withdrawn	`NCT04030624` - Remote Electronic Patient Monitoring in Gastrointestinal Cancer	N/A
Completed	`NCT02140593` - The Laparotomy Study	Phase 4
Completed	`NCT02222259` - A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients	N/A
Active, not recruiting	`NCT00716209` - Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers	N/A
Recruiting	`NCT01484444` - Biomarker Analysis of Gastrointestinal Cancer	N/A
Completed	`NCT02130427` - A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy	N/A
Active, not recruiting	`NCT00710632` - Screening to Predict Weight Loss in Patients With Cancer	N/A
Completed	`NCT00094965` - Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function	Phase 2
Terminated	`NCT04077372` - Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers	N/A
Recruiting	`NCT04899908` - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases	Phase 2
Recruiting	`NCT05429866` - Immunological Variables Associated to ICI Toxicity in Cancer Patients	Phase 2
Recruiting	`NCT05226221` - Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality
Recruiting	`NCT03286348` - Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Avatrombopag vs. Placebo for CIT in GI Malignancies — ACT-GI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms